1-4 of 4
Nathan Standifer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Julio C. Chavez, Francine M. Foss, Basem M. William, Jonathan E. Brammer, Sonali M. Smith, Anca Prica, Jasmine M. Zain, Joseph M. Tuscano, Harsh Shah, Neha Mehta-Shah, Praveen Ramakrishnan Geethakumari, Ben X. Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao, Shringi Sharma, Gianluca Carlesso, Jeffrey A. Moscow, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1869–1878.
https://doi.org/10.1158/1078-0432.CCR-22-2955
Published: 15 May 2023
View articletitled, Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Open the PDF for Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song, Robin Kate Kelley, Anis A. Khan, Nathan Standifer, Diansong Zhou, KyoungSoo Lim, Rajesh Krishna, Lu Liu, Kun Wang, Patricia McCoon, Alejandra Negro, Philip He, Megan Gibbs, John F. Kurland, Ghassan K. Abou-Alfa
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 754–763.
https://doi.org/10.1158/1078-0432.CCR-22-1983
Published: 16 February 2023
View articletitled, Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Open the PDF for Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2567–2578.
https://doi.org/10.1158/1078-0432.CCR-21-4064
Published: 13 June 2022
View articletitled, Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Open the PDF for Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani S. Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio González-García, Nathan Standifer, Jennifer Cann, Nicholas Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6196–6203.
https://doi.org/10.1158/1078-0432.CCR-20-0452
Published: 01 December 2020
View articletitled, Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors in another window
Includes: Supplementary data